Our results showed that patients with anti-GBM disease combined with IgA deposition in the mesangial region have no statistical difference in the treatment of classical anti-GBM patients (Initial dialysis treatment: p=0.06; Number of plasma exchanges:p=0.537; Plasmapheresis: p = 0.665; pulse methylprednisolone:p=0.119; Oral steroid:p=0.504; Cyclophosphamide: p = 0.394; Rituximab, p = 0.24; Mycophenolate mofetil:p=1). This evidence concerns the gene CD79A and glioblastoma.